Which human ageing phenotypes are causally reversible by mTOR modulation — and is it the same mechanism in each tissue?

Human-endpoint gap · evidence stands at: Clinical outcome in humans — mixed and partly negative · Atlas ID F5

The gap

Asking whether a drug makes people live longer cannot be answered in any reasonable amount of time, and aiming at it has crowded out better questions. Ageing is not one thing: the immune system, muscle, metabolism and the brain each age in their own way, and a drug might reach some of them and miss others entirely.

Technical framing: Does rapamycin extend human lifespan is not a testable question on any useful timescale, and treating it as the goal has let a set of much sharper questions go unasked. Immune ageing, sarcopenia, metabolic dysfunction, neurodegeneration, fibrosis and stem-cell exhaustion are separate phenotypes with separate readouts, and there is no reason to assume one drug reaches them all or reaches them by the same route.

What changed

The human results that have arrived are tissue-specific and they do not agree with each other. A phase 3 trial of low-dose TORC1 inhibition failed to reduce respiratory infections in older adults (Mannick, Lancet Healthy Longev 2021, PMID 33977284). In the brain, one 2025 trial found rapamycin undetectable in cerebrospinal fluid, while CSF p-tau181, GFAP and neurofilament light rose (Gonzales, Commun Med 2025, PMID 40394335), and a second found no change in cerebral glucose metabolism on FDG-PET (Svensson, medRxiv 2025, preprint). Brain exposure was never demonstrated. In muscle, 48 weeks of intermittent dosing raised lean mass in women rather than lowering it (Moel, Aging 2025, PMID 40188830). Same drug, three tissues, three different kinds of answer.

What is still open

Which phenotypes are reachable at tolerable exposure, and whether the mechanism is shared. The pattern in the failures is worth naming on its own: both the immune and the brain trials failed upstream of efficacy, at target engagement, not at mechanism. So the prior question is what counts as demonstrated mTOR target engagement in a given human tissue — and no trial that has failed so far was designed to answer it.

How it could be tested

Phenotype-first rather than drug-first. Pick one tissue where target engagement can be demonstrated directly — skin, blood or muscle, all biopsiable — fix the regimen against a measured pharmacodynamic endpoint in that tissue, and only then test a functional outcome. Run the same design across tissues and compare the pharmacodynamic signature that accompanies benefit in each. Whether the signature is shared answers the mechanism half.

Why it matters

It replaces one unanswerable question with several answerable ones, and it explains the run of negative human trials as an exposure problem rather than a refutation of the biology.

Bears on these open questions

• A sensor/autophagy biomarker panel as a surrogate endpoint for human trials
• Low-dose mTOR inhibition rejuvenates the aging immune system without net immunosuppression
• Brain-penetrant mTOR inhibition clears aggregates in models, but human dosing has not been shown to reach the brain — and mTORC2 is needed for memory in mice

← All frontier questions · Open questions